NeuroSense Therapeutics Ltd. (NRSNW)Herzliya, Israel | NasdaqCM
0.07 USD
|
Hot Take ↕ | Aug. 22, 2026, 4:52 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic collapse in share price over the last two weeks, dropping from $0.21 to $0.04, which suggests a liquidity crisis or a massive de-rating event that overrides any potential catalysts like the CFO's insider purchase. Fundamentally, the company is in distress with negative book value, a current ratio of just 0.31 indicating insolvency risks, and massive cash burn with no free cash flow generation. There is no dividend to speak of, and the lack of historical price data prevents any assessment of long-term business quality or recovery trends, leaving the investment case entirely unsupported. |
| Attribute | Value |
|---|---|
| Beta | 1.60 |
| Website | https://www.neurosense-tx.com |
| Attribute | Value |
|---|---|
| Address1 | Building B |
| Address2 | 11 HaMenofim Street |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 1.598 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -0.048 |
| City | Herzliya |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.07 |
| Current Ratio | 0.309 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.07 |
| Day Low | 0.045 |
| Display Name | NeuroSense Therapeutics |
| Ebitda | -11,069,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -0.935 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.07 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.045 |
| Fifty Two Week Low Change | 0.024999999 |
| Fifty Two Week Low Change Percent | 0.5555555 |
| Fifty Two Week Range | 0.045 - 0.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 23,870,668 |
| Free Cashflow | -3,869,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 0.07 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,021-12-09 |
| Language | en-US |
| Long Business Summary | NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. |
| Long Name | NeuroSense Therapeutics Ltd. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_551904618 |
| Net Income To Common | -11,125,000 |
| Open | 0.3 |
| Operating Cashflow | -7,671,000 |
| Operating Margins | 0.0 |
| Phone | 972 9 799 6183 |
| Previous Close | 0.07 |
| Price Hint | 4 |
| Price To Book | -1.4583334 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.079 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.07 |
| Regular Market Day Low | 0.045 |
| Regular Market Day Range | 0.045 - 0.07 |
| Regular Market Open | 0.3 |
| Regular Market Previous Close | 0.07 |
| Regular Market Price | 0.07 |
| Regular Market Time | 1,787,947,014 |
| Regular Market Volume | 1,706 |
| Return On Assets | -2.47301 |
| Return On Equity | -21.749762 |
| Sand P52 Week Change | 0.20204377 |
| Sector | |
| Sector Key | |
| Short Name | NEUROSENSE THERAPEUTICS LTD C/W |
| Source Interval | 15 |
| Symbol | NRSNW |
| Total Cash | 166,000 |
| Total Cash Per Share | 0.005 |
| Total Debt | 170,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.935 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 1,706 |
| Website | https://www.neurosense-tx.com |
| Zip | 4,672,562 |